N/A N=28 Randomized Treatment

Piloting Healthcare Coordination in Hypertension

Hypertension

Bottom Line

View on ClinicalTrials.gov: NCT02988193 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Sep 2019

Primary outcome: Primary: Clinical Adoption of a Decision Support Artificial Intelligence — 10; 3 Participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: optima4BP Medication Management (Device)
Age: Adult, Older Adult · 21+ yrs
Sex: All
Sponsor: Optima Integrated Health
Primary completion: Jan 2017

Outcome Measures

Outcome	Result	p-value
PRIMARY Clinical Adoption of a Decision Support Artificial Intelligence	10; 3	—

Summary

The PRECISION study investigates the possibility of integrating a clinical decision support analytic intelligence into the clinical care flow at University of California San Francisco Medical Center (UCSF MC). optima-for-blood pressure [optima4BP], our innovation, transforms the episodic and reactive nature of uncontrolled HTN pharmacological treatment management into a process that is continuous, proactive, and personalized. In addition, the clinical adoption of this "technology of the future" will be investigated to establish its feasibility in being embedded into the clinical care flow. Today's hypertension (HTN) management paradigm often fails to align current patient health status with the most effective medication treatment. Without surveillance and rapid-cycles analysis of current patient health status and treatment efficacy, HTN management remains a struggle. optima4BP addresses pharmacological intervention management by identifying the need for a drug treatment change and recommending the most appropriate drug optimization. The PRECISION study represent a pilot trial intended to address 2 critical design components of optima4BP: 1. Can optima4BP interoperate with multiple IT platforms to collect and distribute data? 2. What is the treating physician confidence in using optima4BP?

Eligibility Criteria

Inclusion Criteria

UCSF General Medicine patient
2 or more values on consecutive office visits within 12 months: systolic blood pressure (SBP) > 140 mmHg or diastolic blood pressure (DBP) > 90
Therapy with at least 2 anti-hypertensive pharmacological classes at the time of the last office visit

Exclusion Criteria

Does not own a smartphone
Does not speak or read English
Planning to leave UCSF in the next year
Has a treating physician who refuses to enroll patients
Treating physician states that:

Patient cannot manage Qardio® arm blood pressure (BP) device (due to cognitive, psychological, physical or other problems), or Patient is already at goal, or Should not participate in the study for any other reason

Non-compliance with medical follow-up (frequent "no shows")
Planned coronary revascularization in the next 6 months
Myocardial infarction, stroke, coronary revascularization, cardiac or aortic surgery in the last 3 months

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02988193). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.